Please assess the completion status of the following clinical trial:

Trial Title: Study of Real Clinical Practice to Evaluate the Effects of Oral Dydrogesterone for Treatment of Confirmed Endometriosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female, aged ≥ 18 years and ≤ 45 years.~* Complaints on chronic pelvic pain with or without dysmenorrhea assessed by 11-items NRS.~* External genital endometriosis confirmed by laparoscopy.~* Existing pelvic (vaginal) ultrasound data not earlier than 2 months before inclusion in the study.~* Prescribed treatment with Duphaston® according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle or continuously.~* No hormonal treatment in 2 cycles before enrollment.~* Signed Patient Authorization for Use/Disclosure of Data.~Exclusion Criteria:~* Any co-existing disease(s) needing chronic drug therapy (e.g. Crohn's disease, diabetes etc); Severe concomitant medical illness.~* Severe other genital pathology excluding endometriosis (e.g. Multiple/severe myoma; adenomyosis, inflammatory diseases, etc.).~* Routine consumption of analgesics other than for the pain of endometriosis.~* Patients receiving hormonal contraceptives in last 2 cycles (including intrauterine devices, contraceptive patches, contraceptive rings, oral contraceptives etc.).~* Ongoing pregnancy.~* Menopause or premature ovarian failure.~* Contraindications to dydrogesterone treatment listed in the locally approved label (Instructions for the medical use of Duphaston®).~* Any other condition that precludes use of dydrogesterone in a particular patient, in accordance with the precautions and special warnings listed in the locally approved label (Instructions for the medical use of Duphaston®).~* Abnormal results of pap smear test.~* Other conditions that made the patients participation impossible (based on the investigator decision).~* Fertility treatments using assisted reproductive technology.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Endometriosis/Dydrogesterone (Type: None): Females aged 18 to 45 years, suffering external genital endometriosis confirmed by laparoscopy, for whom were prescribed treatment with Duphaston®

Based on this trial design, predict the completion outcome and termination type (if applicable).